Supplementary information

The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity

In the format provided by the authors and unedited

NK cells Gating Strategy NK cells Live 99.6 NK1.1 11.0 COI 72.5 BV421 - NK1.1 BV605 - CD45, 10 10 10 Single Cells 90.1 1.5M 10 105 SSC-H Viability FSC-A 1 10 CD45+ 28.8 0 PE-Cy5 - CD4 FSC-H FSC-H FSC-H FSC-H Foxp3+/Foxp3- cells Gating Strategy CD4 T cells Live 99.9 Foxp3+ CD4 T cells 46.9 COI 84.1 CD4 T cells 3.46 APC-Cy7 - CD4 BV605 - CD45 APC - Foxp3 Viability SSC-H FSC-A Single Cells 74.5 CD45-20.7 Foxp3- CD4 T ci 51.1 FSC-H FSC-H FSC-H FSC-H PE-Cy5 - T cell Receptor FSC-A TOX Gating Strategy CD8 T cells CD8 T cells 2.37 Live 99.2 Single Cells 93.7 COI 62.0 1.5M BV785 - CD8 10 PE - TOX SSC-H Viability FSC-A 1.0M 9.8 FSC-H FSC-H FSC-H PE-Cy5 - T cell Receptor BV421 - TIM3 pSTAT5 Gating Strategy CD8 T cells TCRb+CD8+ BV785 - CD8 APC - CD45 105 105 SSC-A FSC-H Single Cells 96.9 10 10 COI 34.4 0 FSC-A FSC-A Viability PE-Cy5 - T cell Receptor

а











Extended Data Figure 1e



Extended Data Figure 1o



Extended Data Figure 1p









Extended Data Figure 8g

Extended Data Figure 8h

260 kDa 160 kDa	1hr 20hr IL2+ IL2+ NTX IL2 AC484 AC484 AC484	AC484 IFNγ IL2	- 0.1uM 0.5uM 20uM - + + + + - +
	pSTAT5 (90 kDa)	260 kDa 💳	
90 KDa		160 kDa 🗕 📩	
70 kDa		125 kDa	pSTAT5 (90 kDa)
50 kDa	α-tubulin (50 kDa)	90 kDa 🛛 🗕 🚽 70 kDa 🖉	
38 kDa		50 kDa 🚥	
30 kDa			
25 kDa		38 kDa 🛛 🗕 🗩	and the set of the set of the
LONDU		30 kDa 📥	
15 kDa		25 kDa 🚥	
			• • • • • • • • • • • • • • • • • • •

Supplementary Figure 1.

a. Gating strategy for NKCs, Foxp3^{+/}Foxp3⁻, TOX/TIM3 and pSTAT5 in Figure 6a-b.
b. Gating strategy for NKCs, CD8 T cells and macrophages in Extended Data Figure 8b-e.

c. Full western blot scans with MW markers for Figure 6f, Extended Data Figure 1e, o, and p and Extended Data Figure 8g and h.